---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-037134"
form_type: "8-K"
ticker: "OM"
cik: "0001484612"
company_name: "Outset Medical, Inc."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T12:53:03.690948+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Outset Medical Q2 revenue $36M (+44% YoY); pauses TabloCart shipment pending 510(k) clearance

## Summary
- Q2 net revenue $36.0M, up 44% YoY; product revenue $29.3M (+49.5%).
- Gross margin improved to 21.4% (22.5% non-GAAP) from 15.1% YoY.
- Net loss $44.0M ($0.90/share) vs $43.8M ($0.92) YoY.
- Paused shipment of TabloCart with Prefiltration pending FDA 510(k) clearance; plans to file later this month.
- Reiterated 2023 revenue guidance $144-150M but expects low end due to pause.

## SEC filing metadata
- accession: 0000950170-23-037134
- form_type: 8-K
- ticker: OM
- cik: 0001484612
- company_name: Outset Medical, Inc.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484612/000095017023037134/0000950170-23-037134-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484612/000095017023037134/om-20230802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-037134
- JSON: https://secwatch.observer/filing/0000950170-23-037134.json
- Plain text: https://secwatch.observer/filing/0000950170-23-037134.txt

## Key facts
- Earnings Releases
  Outset Medical, Inc. reported the second quarter ended June 30, 2023 results: revenue $36.0 million, net income ($44.0) million, EPS ($0.90) per share. Guidance reaffirmed.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $36.0 million
  - Net income: ($44.0) million
  - EPS: ($0.90) per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights • Recorded net revenue of $36.0 million in the second quarter, a 44% increase compared to $25.1 million in the second quarter of 2022, and an 8% increase compared to $33.5 million in the first quarter of 2023. •
  evidence_url: https://www.sec.gov/Archives/edgar/data/1484612/000095017023037134/0000950170-23-037134-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.